Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PGT 121

X
Drug Profile

PGT 121

Alternative Names: PGT121

Latest Information Update: 24 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theraclone Sciences
  • Developer Centre for the AIDS Programme of Research in South Africa; International AIDS Vaccine Initiative; The Ragon Institute of MGH, MIT and Harvard
  • Class Antivirals; Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action HIV envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 03 Mar 2024 Efficacy data from a phase I/IIa trial in HIV infections presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024 Session (CROI-2024)
  • 02 May 2022 International AIDS Vaccine Initiative completes a phase I/IIa trial in HIV infections (Combination therapy) in USA (IV) (NCT03721510)
  • 12 Feb 2022 Pharmacodynamics data from preclinical trials in HIV infection presented at the 29th Conference on Retroviruses and Opportunistic Infections (CROI-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top